GSK plans to restructure in Belgium with over 1,200 jobs at risk
GSK is restructuring its Belgium operations, putting over 1,200 research and support jobs at risk while sparing manual roles.
Layoffs · Source: Reuters
What happened
British pharmaceutical company GSK announced plans to restructure its operations in Belgium. The proposed reorganization puts more than 1,200 jobs at risk. The company currently employs 8,500 people across the country. These workers are spread across major sites in Wavre, Rixensart, and Gembloux. The announcement came on Wednesday and immediately raised concerns for the local workforce.
The planned cuts will target specific departments rather than the entire company. Research and development teams will face significant changes. Manufacturing support and international support functions will also see their headcounts evaluated. GSK explicitly confirmed that manual jobs are not included in this reorganization plan. Factory floor workers who physically produce the vaccines remain secure for now.
The company is framing this move as a strategic shift rather than a simple workforce reduction. GSK stated it wants to redirect its resources toward its most promising medicines and vaccines. The primary goal is to simplify the organization structure. Management believes these changes will allow the company to operate more efficiently and remain competitive in the global pharmaceutical market.
By the numbers
- More than 1,200 — Jobs at risk in the proposed restructuring
- 8,500 — Total people employed by GSK in Belgium
- Wavre, Rixensart, and Gembloux — GSK site locations in Belgium affected by the news
Why it matters
This situation shows how large pharmaceutical companies are shifting their focus and budgets. Even in highly specialized fields like research and development, jobs are not completely safe. When a company decides to pivot its strategy toward specific products, entire departments can be restructured. For job seekers in pharma and biotech, this means hiring might slow down in general research. At the same time, hiring could speed up in highly targeted vaccine or medicine projects that have proven potential.
The clear distinction between manual jobs and support functions highlights a growing trend in corporate restructuring. Companies are protecting the workers who physically make the products. Meanwhile, they are trimming the teams that manage, research, or support operations internationally. Professionals in support or international roles may face tighter job markets. You will need to clearly prove how your role directly supports the bottom line as companies look to simplify their organizational charts.
Who this hits
Research and development professionals
Scientists and researchers at GSK in Belgium face direct risk from this proposed restructuring. Those looking for R&D roles in the broader pharmaceutical sector may see increased competition as these experienced workers enter the job market.
International support staff
Corporate and international support teams are a primary target for these upcoming cuts. Professionals in administrative or management roles will need to prove their direct value to core business goals to remain competitive.
Manual workers
Manual workers at the Belgium sites are entirely excluded from the proposed reorganization. Their jobs remain secure as the company continues to rely on them to physically manufacture its medicines and vaccines.
What to do this week
- If you work in pharma research and development, align your resume with the specific medicines or vaccines that companies are prioritizing right now.
- Support staff should update their portfolios to highlight how their work directly improves operational efficiency or reduces costs for the business.
- Set up job alerts for specialized roles in targeted vaccine development, as companies like GSK are actively redirecting their resources there.
- Network with recruiters in the manufacturing sector, as manual and production roles remain highly secure and in demand during these corporate shifts.
See who's hiring right now on GiraffyReach
My take
Companies will always frame job cuts as a strategic pivot. When GSK says they are redirecting resources, it simply means they are cutting roles that do not serve their immediate product goals. If you are looking for work, you must position yourself as essential to the core products a company wants to build next.